September 23, 2019
GW paves way to launch Epidylex in Europe
GW Pharmaceuticals paved a way to launch Epidyolex in Europe, for use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older.